Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2025-06-27 Governance Information
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 82% confidence The document is a standalone announcement listing the company’s board members, their positions (executive, non-executive, independent) and committee memberships. It focuses on the board structure and governance roles rather than reporting quarterly results, legal matters or share transactions. This fits the Governance Information category (CGR).
2025-06-27 English
CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE
Board/Management Information Classification · 95% confidence The document is a formal announcement by the company’s Board of Directors of a change in membership of its Nomination Committee, specifying who ceased and who was appointed. This type of announcement falls squarely under Board/Management Information (MANG), as it details changes in the board committee composition. It is not an AGM presentation, full report, earnings release, or other category.
2025-06-27 English
POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING HELD ON JUNE 27, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled “Poll Results of the 2024 Annual General Meeting held on June 27, 2025” and consists solely of the voting outcomes for ordinary and special resolutions proposed at the AGM. It is not the AGM presentation materials (AGM-R), nor a financial report, but the official announcement of shareholder vote results. This matches the Declaration of Voting Results & Voting Rights Announcements category.
2025-06-27 English
INSIDE INFORMATION ANNOUNCEMENT GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE
Share Issue/Capital Change Classification · 85% confidence The document is an official announcement of the listing approval granted by the Stock Exchange for the conversion and listing of unlisted shares into H shares, including detailed shareholding structure post-conversion. This relates directly to a change in the company’s share capital and issuance structure rather than financial results, dividend, or management changes. According to the definitions, announcements regarding new share issues, conversions, or other capital structure changes fall under Share Issue/Capital Change (Code: SHA).
2025-06-19 English
RESIGNATION OF NON-EXECUTIVE DIRECTOR AND PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 92% confidence The document is a public announcement by Lepu Biopharma Co., Ltd. concerning the resignation of a non-executive director and the proposed appointment of a new non-executive director. It details board composition changes, biographies, and shareholder approval at the upcoming AGM. This directly matches the category for announcements of changes in the board of directors or senior management (Board/Management Information).
2025-06-06 English
Proxy Form for the Annual General Meeting to be held on June 27 2025
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a proxy form for the company’s upcoming Annual General Meeting, providing shareholders with instructions to appoint a proxy and vote on resolutions. This is part of the materials sent to shareholders to solicit their votes (Proxy Solicitation & Information Statement).
2025-06-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.